Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Ascites 1

Interventions

Oxaliplatin 10Capecitabine 9Cisplatin 8Fluorouracil 5Leucovorin 4Bevacizumab 4tegafur-gimeracil-oteracil 3pemigatinib 3atezolizumab 3Nivolumab 3trebananib 2ponatinib 2pembrolizumab 2avelumab 2apatinib 2alectinib 2XELOX 2Standard of Care 2S 1 (combination) 2Radiotherapy 2Radiosurgery 2Ocoxin 2Irinotecan 2Ipilimumab 2Gemcitabine 2Folfox protocol 2Everolimus 2Erlotinib Hydrochloride 2Acupuncture Therapy 2zanidatamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastrointestinal Neoplasms × danvatirsen × Clear all
NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
1 enrolled 10 charts
GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡